Latent Tuberculosis Infection (LTBI) and Its Potential Targets: An Investigation into Dormant Phase Pathogens.
作者： Gopichand Gutti , Karan Arya , Sushil Kumar Singh
DOI: 10.2174/1389557519666190625165512
关键词:
摘要: One-third of the world's population harbours latent tuberculosis infection (LTBI) with a lifetime risk reactivation. Although, treatment LTBI relies significantly on first-line therapy, identification novel drug targets and therapies are emerging focus for researchers across globe. The current review provides an insight into infection, diagnostic methods epigrammatic explanations potential molecular dormant phase bacilli. This study also includes preclinical clinical aspects tubercular infections new approaches in antitubercular discovery.
eurekaselect.com参考文章(122)
Gary Slutkin, Eliseo J. Perez-Stable, Philip C. Hopewell, Time course and boosting of tuberculin reactions in nursing home residents. The American review of respiratory disease. ,vol. 134, pp. 1048- 1051 ,(1986) , 10.1164/ARRD.1986.134.5.1048
Parthiban Brindha Devi, Jonnalagadda Padma Sridevi, Shruti Singh Kakan, Shalini Saxena, Variam Ullas Jeankumar, Vijay Soni, Hasitha Shilpa Anantaraju, Perumal Yogeeswari, Dharmarajan Sriram, Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis Tuberculosis. ,vol. 95, pp. 786- 794 ,(2015) , 10.1016/J.TUBE.2015.04.010
Sudha Ravishankar, Anisha Ambady, Disha Awasthy, Naina Vinay Mudugal, Sreenivasaiah Menasinakai, Sandesh Jatheendranath, Supreeth Guptha, Sreevalli Sharma, Gayathri Balakrishnan, Radha Nandishaiah, Vasanthi Ramachandran, Charles J. Eyermann, Folkert Reck, Suresh Rudrapatna, Vasan K. Sambandamurthy, Umender K. Sharma, Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target. Tuberculosis. ,vol. 95, pp. 589- 598 ,(2015) , 10.1016/J.TUBE.2015.05.004
C Kendall Stover, Paul Warrener, Donald R VanDevanter, David R Sherman, Taraq M Arain, Michael H Langhorne, Scott W Anderson, J Andrew Towell, Ying Yuan, David N McMurray, Barry N Kreiswirth, Clifton E Barry, William R Baker, None, A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. ,vol. 405, pp. 962- 966 ,(2000) , 10.1038/35016103
Peter Andersen, T. Mark Doherty, The success and failure of BCG - implications for a novel tuberculosis vaccine. Nature Reviews Microbiology. ,vol. 3, pp. 656- 662 ,(2005) , 10.1038/NRMICRO1211
Hideyuki Hayashi, Pyridoxal Enzymes: Mechanistic Diversity and Uniformity Journal of Biochemistry. ,vol. 118, pp. 463- 473 ,(1995) , 10.1093/OXFORDJOURNALS.JBCHEM.A124931
Vivek Sharma, Sujata Sharma, Kerstin Hoener zu Bentrup, John D. McKinney, David G. Russell, William R. Jacobs, James C. Sacchettini, Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis Nature Structural & Molecular Biology. ,vol. 7, pp. 663- 668 ,(2000) , 10.1038/77964
J. Rengarajan, B. R. Bloom, E. J. Rubin, Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages Proceedings of the National Academy of Sciences of the United States of America. ,vol. 102, pp. 8327- 8332 ,(2005) , 10.1073/PNAS.0503272102
Philana Ling Lin, JoAnne L. Flynn, Understanding Latent Tuberculosis: A Moving Target Journal of Immunology. ,vol. 185, pp. 15- 22 ,(2010) , 10.4049/JIMMUNOL.0903856
Haruaki Tomioka, Katsumasa Sato, Tatsuya Akaki, Hiroko Kajitani, Shin Kawahara, Mitsunori Sakatani, Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrobial Agents and Chemotherapy. ,vol. 43, pp. 3001- 3004 ,(1999) , 10.1128/AAC.43.12.3001